The effect of miRNA and autophagy on colorectal cancer
- PMID: 32914514
- PMCID: PMC7574865
- DOI: 10.1111/cpr.12900
The effect of miRNA and autophagy on colorectal cancer
Abstract
Colorectal cancer (CRC) has become a concern because of its high recurrence rate and metastasis rate, low early diagnosis rate and poor therapeutic effect. At present, various studies have shown that autophagy is closely connected with the occurrence and progression of CRC. Autophagy is a highly cytosolic catabolic process involved in lysosomes in biological evolution. Cells degrade proteins and damaged organelles by autophagy to achieve material circulation and maintain cell homeostasis. Moreover, microRNAs are key regulators of autophagy, and their mediated regulation of transcriptional and post-transcriptional levels plays an important role in autophagy in CRC cells. This review focuses on the recent research advances of how autophagy and related microRNAs are involved in affecting occurrence and progression of CRC and provides a new perspective for the study of CRC treatment strategies.
Keywords: autophagy; colorectal cancer; microRNA; therapy.
© 2020 The Authors. Cell Proliferation published by John Wiley & Sons Ltd.
Conflict of interest statement
None.
Figures

Similar articles
-
MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2.J Pathol. 2014 Mar;232(4):415-27. doi: 10.1002/path.4309. J Pathol. 2014. PMID: 24293274
-
Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling.BMC Cancer. 2015 Nov 19;15:919. doi: 10.1186/s12885-015-1929-y. BMC Cancer. 2015. PMID: 26585594 Free PMC article.
-
SNHG14 stimulates cell autophagy to facilitate cisplatin resistance of colorectal cancer by regulating miR-186/ATG14 axis.Biomed Pharmacother. 2020 Jan;121:109580. doi: 10.1016/j.biopha.2019.109580. Epub 2019 Nov 5. Biomed Pharmacother. 2020. PMID: 31704614
-
MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside.World J Gastroenterol. 2018 Jul 21;24(27):2949-2973. doi: 10.3748/wjg.v24.i27.2949. World J Gastroenterol. 2018. PMID: 30038463 Free PMC article. Review.
-
May autophagy be a novel biomarker and antitumor target in colorectal cancer?Biomark Med. 2016 Oct;10(10):1081-1094. doi: 10.2217/bmm-2016-0083. Epub 2016 Sep 14. Biomark Med. 2016. PMID: 27626110 Review.
Cited by
-
Construction of a Novel MYC-Associated ceRNA Regulatory Network to Identify Prognostic Biomarkers in Colon Adenocarcinoma.J Oncol. 2022 Jul 5;2022:3216285. doi: 10.1155/2022/3216285. eCollection 2022. J Oncol. 2022. PMID: 35847359 Free PMC article.
-
In situ imaging of intracellular miRNAs in tumour cells by branched hybridisation chain reaction.Cell Prolif. 2024 Dec;57(12):e13721. doi: 10.1111/cpr.13721. Epub 2024 Jul 22. Cell Prolif. 2024. PMID: 39034809 Free PMC article.
-
Microcystin‑leucine arginine promotes colorectal cancer cell proliferation by activating the PI3K/Akt/Wnt/β‑catenin pathway.Oncol Rep. 2023 Jan;49(1):18. doi: 10.3892/or.2022.8455. Epub 2022 Dec 1. Oncol Rep. 2023. PMID: 36453240 Free PMC article.
-
Lysine demethylase 5C inhibits transcription of prefoldin subunit 5 to activate c-Myc signal transduction and colorectal cancer progression.Mol Med. 2024 Jan 12;30(1):9. doi: 10.1186/s10020-023-00775-7. Mol Med. 2024. PMID: 38216914 Free PMC article.
-
Mesangial Cell-Derived Exosomal miR-4455 Induces Podocyte Injury in IgA Nephropathy by Targeting ULK2.Oxid Med Cell Longev. 2022 Nov 4;2022:1740770. doi: 10.1155/2022/1740770. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 36388165 Free PMC article.
References
-
- Sung JJY, Ng SC, Chan FKL, et al. An updated Asia Pacific Consensus Recommendations on colorectal cancer screening. Gut. 2015;64:121‐132. - PubMed
-
- Punt CJ, Koopman M, Vermeulen L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol. 2017;14:235‐246. - PubMed
-
- O'connell J, Bennett MW, Nally K, et al. Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor‐immune conflict. Ann N Y Acad Sci. 2000;910(178–192):193‐195. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical